Equity Overview
Price & Market Data
Price: $0.671
Daily Change: -$0.038 / 5.67%
Range: $0.654 - $0.93
Market Cap: $3,349,583
Volume: 2,481,711
Performance Metrics
1 Week: -8.90%
1 Month: -11.14%
3 Months: -28.67%
6 Months: -61.69%
1 Year: -85.70%
YTD: -59.36%
Company Details
Employees: 8
Sector: Health technology
Industry: Pharmaceuticals: major
Country: United States
Details
Palisade Bio, Inc., a clinical-stage biopharmaceutical company, focuses on developing and advancing novel therapeutics for patients living with autoimmune, inflammatory, and fibrotic diseases. The company's lead therapeutic candidate is PALI-2108, a prodrug PDE4 inhibitor that is in phase 1a/b clinical trial for the treatment of ulcerative colitis, as well as under phase 1a clinical trial for the treatment of fibrostenotic crohn's disease. It has a research collaboration and license agreement with Giiant Pharma, Inc. for the development, manufacture, and commercialization of its compounds; a license agreement with the Regents of the University of California for sole purpose of maintaining the Newsoara Co-Development; and a co-development and distribution agreement with Newsoara Biopharma Co., Ltd. The company is headquartered in Carlsbad, California.